Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19-IL2 in Advanced Solid Tumors
NCT01058538Phase 2Completed
- Sponsor
- Philogen
- Start
- Nov 2005
- Primary completion
- Apr 2008
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 2 trial of darleukin in solid tumor, renal cell carcinoma (RCC), sponsored by Philogen. Started Nov 2005; status: completed.
02
Drugs
darleukin
03
Conditions
solid tumorrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01058538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01058538.